期刊
JOURNAL OF IMMUNOLOGY
卷 173, 期 5, 页码 2933-2941出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.173.5.2933
关键词
-
类别
资金
- NCI NIH HHS [CA39201] Funding Source: Medline
- NCRR NIH HHS [RR11576] Funding Source: Medline
- NHLBI NIH HHS [R01 HL63452, 2R37 HL56067] Funding Source: Medline
- NIAID NIH HHS [R01 AI 34495, AI46689, P01 AI35225, AI/DK49829] Funding Source: Medline
CD30, a TNFR family member, is expressed on activated CD4(+) and CD8(+) T cells and B cells and is a marker of Hodgkin's lymphoma; its ligand, CD30L (CD153) is expressed by activated CD4(+) and CD8+ T cells, B cells, and macrophages. Signaling via CD30 can lead to proliferation or cell death. CD30-deficient (-/-) mice have impaired thymic negative selection and increased autoreactivity. Although human alloreactive T cells preferentially reside within the CD30(+) T cell subset, implicating CD30 as a regulator of T cell immune responses, the role of CD30/CD153 in regulating graft-vs-host disease (GVHD) has not been reported. We used a neutralizing anti-CD153 mAb, CD30(-/-) donor mice, and generated CD153(-/-) recipient mice to analyze the effect of CD30/CD153 interaction on GVHD induction. Our data indicate that the CD30/CD153 pathway is a potent regulator of CD4+, but not CD8(+), T cell-mediated GVHD. Although blocking CD30/CD153 interactions in vivo did not affect alloreactive CD4+ T cell proliferation or apoptosis, a substantial reduction in donor CD4+ T cell migration into the gastrointestinal tract was readily observed with lesser effects in other GVHD target organs. Blockade of the CD30/CD153 pathway represents a new approach for preventing CD4(+) T cell-mediated GVHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据